George C. Bobustuc
Expertise in
25
conditions

Dr. George C. Bobustuc

Neurology
880 W. Central Rd., Suite 7200, 
Arlington Heights, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Referral may be required
Before you request
Expertise in
25
conditions
880 W. Central Rd., Suite 7200, 
Arlington Heights, IL 

Overview

George Bobustuc is a Neurologist practicing medicine in Arlington Heights, Illinois.

Dr. Bobustuc is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Brain Tumor, Glioma, and Awake Craniotomy.

Dr. Bobustuc is board certified in American Board Of Psychiatry And Neurology and United Council For Neurologic Subspecialties. He is actively involved in clinical research, co-authoring 15 peer reviewed articles and participating in 10 clinical trials. Dr. Bobustuc is currently accepting new patients.

Specialties

Neurology

Licenses

Internal Medicine in WI

Board Certifications

American Board Of Psychiatry And Neurology
United Council For Neurologic Subspecialties

Fellowships

University of Texas M.D. Anderson Cancer Center, Neurological Oncology, 2001

Hospital Affiliations

Northwest Community Hospital 1
Swedish Hospital
Northshore University Healthsystem - Evanston Hospital

Languages Spoken

English
Romanian
Ron

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Celtic
  • HMO
  • INSURANCE PLAN
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
FirstCare
  • HMO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Network Health
  • HMO
Oscar
  • EPO
  • HMO
  • PPO
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Endeavor Health Medical Group
880 W. Central Rd., Suite 7200, Arlington Heights, IL 60005
Other Locations
Endeavor Health Medical Group
2650 Ridge Ave., Kellogg Cancer Center, Evanston, IL 60201
Endeavor Health Medical Group
2180 Pfingsten Rd., Kellogg Cancer Center, Glenview, IL 60026

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Drug
Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib
Study Phase: Phase 2
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Enrollment Status: Active_not_recruiting
Publish Date: June 10, 2026
Intervention Type: Other, Drug
Study Drugs: Vemurafenib, Cobimetinib
Study Phase: Phase 2
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 15, 2026
Intervention Type: Drug
Study Drugs: Berubicin, Lomustine
Study Phase: Phase 2
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: October 31, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Enrollment Status: Terminated
Publish Date: January 24, 2025
Intervention Type: Biological, Drug
Study Drugs: HSPPC-96, Bevacizumab
Study Phase: Phase 2
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate When Added to Standard Temozolomide Treatment in Patients With Newly Diagnosed Resected Unmethylated Glioblastoma Multiforme
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate When Added to Standard Temozolomide Treatment in Patients With Newly Diagnosed Resected Unmethylated Glioblastoma Multiforme
Enrollment Status: Terminated
Publish Date: October 03, 2024
Intervention Type: Drug, Dietary supplement
Study Drugs: Disulfiram, Temozolomide
Study Phase: Phase 2
Feasibility of Aromatherapy in an Awake Craniotomy Environment
Feasibility of Aromatherapy in an Awake Craniotomy Environment
Enrollment Status: Completed
Publish Date: October 03, 2024
Intervention Type: Drug
Study Drug: Lavender
Study Phase: Phase 1
View 9 Less Clinical Trials

15 Total Publications

Correction: Efficacy of local convection enhanced delivery of chemotherapy using an intracerebral osmotic pump in a rat model of glioblastoma.
Correction: Efficacy of local convection enhanced delivery of chemotherapy using an intracerebral osmotic pump in a rat model of glioblastoma.
Journal: Frontiers in oncology
Published: March 11, 2026
Similar Doctors
Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

Rush Neurology-Movement Disorders

1725 W Harrison St Ste 755, 
Chicago, IL 
 (20.4 miles away)
312-942-4500
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Cynthia Comella is a Neurologist practicing medicine in Chicago, Illinois. Dr. Comella is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Torticollis, Drug Induced Dyskinesia, Focal Dystonia, and Movement Disorders. Dr. Comella is currently accepting new patients.

Expertise in
63
conditions
Dr. Joyce Y. Wu
Neurology
Expertise in
63
conditions
Dr. Joyce Y. Wu
Neurology
Referral may be required
Before you request

Ann & Robert H. Lurie Children's Hospital Of Chicago

225 E Chicago Ave, 
Chicago, IL 
 (22.5 miles away)
312-227-3550
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients

Joyce Wu is a Neurologist practicing medicine in Chicago, Illinois. Dr. Wu is highly rated in 63 conditions, according to our data. Her clinical expertise encompasses Tuberous Sclerosis, Tuberous Sclerosis Complex, Cortical Dysplasia, and Epilepsy in Children. Dr. Wu is currently accepting new patients.

Expertise in
35
conditions
Expertise in
35
conditions
Referral may be required

Rush University Medical Center

1725 W Harrison St, 
Chicago, IL 
 (21.4 miles away)
312-563-2030
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Christopher Goetz is a Neurologist practicing medicine in Chicago, Illinois. Dr. Goetz is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Parkinson's Disease, Movement Disorders, Drug Induced Dyskinesia, Deep Brain Stimulation, and Cataract Removal. Dr. Goetz is currently accepting new patients.

Frequently Asked Questions about Dr. George C. Bobustuc

How do I make an appointment with Dr. George C. Bobustuc?

You can book an appointment with Dr. George C. Bobustuc by calling their office at 847-618-4430. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. George C. Bobustuc a top-rated expert for Astrocytoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. George C. Bobustuc is classified as an Distinguished expert for Astrocytoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. George C. Bobustuc specialize in?

While Dr. George C. Bobustuc is a Neurology, they have specific expertise in Astrocytoma, Glioblastoma, and Brain Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. George C. Bobustuc participate in research or clinical trials?

Yes. Dr. George C. Bobustuc has published 15 articles and abstracts on conditions like Astrocytoma. You can view a list of Dr. George C. Bobustuc's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. George C. Bobustuc accept my insurance?

Dr. George C. Bobustuc accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 847-618-4430 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bobustuc's expertise for a condition
ConditionClose
    View All 15 Distinguished Conditions
    View All 10 Advanced Conditions
    View All 39 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile